Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 13/20 | 0.47 |
| ▸ | HTR2C | P28335 | 13/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.47 |
| ▸ | DRD2 | P14416 | 10/20 | 0.46 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
| ▸ | HTR1F | P30939 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5871296 | 0.87 | HTR2A (0.47) | HTR2AHTR2CKCNH2DRD2SCD | |
| SCHEMBL5871622 | 0.86 | HTR1A (0.45) | HTR2AHTR2CSCDHTR1AHTR1D | |
| SCHEMBL5871786 | 0.86 | HTR2A (0.54) | HTR2AHTR2CKCNH2DRD2 | |
| SCHEMBL5871055 | 0.83 | HTR2A (0.48) | HTR2AHTR2CKCNH2DRD2SCD | |
| SCHEMBL5871925 | 0.81 | HTR1A (0.49) | HTR2AHTR2CKCNH2DRD2HTR1A | |
| SCHEMBL5871589 | 0.81 | HTR1A (0.58) | HTR2AHTR2CKCNH2DRD2SCD | |
| SCHEMBL5871268 | 0.79 | HTR1A (0.45) | HTR2AHTR2CKCNH2DRD2SCD | |
| SCHEMBL5871190 | 0.78 | SCD (0.52) | HTR2AHTR2CSCDHTR1AHTR1D | |
| SCHEMBL5871235 | 0.77 | HTR2A (0.48) | HTR2AHTR2CKCNH2DRD2 | |
| SCHEMBL5871400 | 0.75 | MCHR1 (0.40) | HTR2AHTR2CKCNH2DRD2SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6579881-B2 | Indoles | EISAI CO., LTD. (JP) | 2003-06-17 | — | — | US | claimed |
| US-20020019531-A1 | Indoles | EISAI CO., LTD. | 2002-02-14 | — | — | US | claimed |
| EP-0976732-A1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-02-02 | — | — | EP | claimed |
| US-7071201-B2 | Serotonin antagonism; muscle relaxant for myotonia; such as 1-(1-(2-(4-methoxyphenyl)ethyl)piperidin-4-yl)-7-methoxy-1,2,3,4 -tetrahydroquinoline | EISAI CO., LTD. (JP) | 2006-07-04 | — | — | US | disclosed |
| EP-0976732-B1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | EISAI CO LTD (JP) | 2004-11-24 | — | — | EP | disclosed |
| US-6579881-B2 | Indoles | EISAI CO., LTD. (JP) | 2003-06-17 | — | — | US | disclosed |
| US-6448243-B1 | SEROTONIN ANTAGONIST FOR TREATING, AMELIORATING AND PREVENTING SPASTIC PARALYSIS OR CENTRAL MUSCLE RELAXANTS FOR AMELIORATING MYOTONIA | EISAI CO., LTD. (JP) | 2002-09-10 | — | — | US | disclosed |
| US-20020086999-A1 | Certain quinoline derivatives | EISAI CO., LTD. | 2002-07-04 | — | — | US | disclosed |
| US-20020019531-A1 | Indoles | EISAI CO., LTD. | 2002-02-14 | — | — | US | disclosed |
| EP-0976732-A1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019531-A1 | Indoles | INMT, MUSK, MB | HTR2A 209/4885HTR2C 222/4885KCNH2 432/4885 |
| US-20020086999-A1 | Certain quinoline derivatives | CHRM1, CHRNA5, CHRNA4 | HTR2A 143/4885HTR2C 107/4885KCNH2 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.